

I1  
cont

(a) a nucleotide sequence coding for the amino acid sequence (SEQ ID NO: 23)

Y C L (X<sub>1</sub> . . . X<sub>n</sub>) S A R Q L T F

in which X<sub>1</sub> . . . X<sub>n</sub> represents a sequence 3-4 of amino acids, wherein the amino acid sequence X<sub>1</sub> . . . X<sub>n</sub> is selected from the group consisting of the amino acid sequences VGG (SEQ. ID NO: 46), VLSG (SEQ. ID NO: 47), ATG (SEQ. ID NO: 48), VSG (SEQ. ID NO: 49), DSG (SEQ. ID NO: 50), VVSG (SEQ. ID NO. 51), ALAG (SEQ. ID NO: 52), APSG (SEQ. ID NO: 53) and VGR SEQ. ID NO: 54), and

(b) a nucleotide sequence which codes for an amino acid sequence with an equivalent recognition specificity, as achieved with a T cell receptor comprising a CDR3 region with the amino acid sequence of SEQ ID NO. 23, for the peptide component of the T cell receptor ligands; wherein the CDR3 region is at least 90% identical with the amino sequence of (a).

I2

4. (Four Times Amended) A Nucleic acid as claimed in claim 2 wherein the amino acid sequence X<sub>1</sub> . . . X<sub>n</sub> is selected from the group consisting of amino acid sequences VGG (SEQ. ID NO: 46), VLSG (SEQ. ID NO: 47) and ATG (SEQ. ID NO: 48).

I3

5. (Three Times Amended) A vector, wherein it contains at least one copy of a nucleic acid as claimed in one of the claims 1 to

4.

I4

7. (Four Times Amended) A cell,

wherein

I4 it is transformed with a nucleic acid as claimed in one of the claims 1 to 4 or with a vector as claimed in claim 5.

I5 26. (Four Times Amended) A pharmaceutical composition which contains as an active component a nucleic acid as claimed in one of the claims 2 or 4, or a cell as claimed in claim 6 or 7 optionally together with other active components as well as common pharmaceutical auxiliary agents, additives or carrier substances.

I6 45. (Amended) An isolated nucleic acid of claim 2 wherein the nucleic acid is purified.

I7 46. (Amended) A nucleic acid as claimed in claim 2 wherein the CDR3 region is (a).